{"organizations": [], "uuid": "258ab51bb4aa6c5c0a929e7549e5dbc162ad44a8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-alexion-pharma-q4-gaap-earnings-pe/brief-alexion-pharma-q4-gaap-earnings-per-share-0-13-idUSASB0C4PP", "country": "US", "domain_rank": 408, "title": "BRIEF-Alexion Pharma Q4 GAAP Earnings Per Share $0.13", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.289, "site_type": "news", "published": "2018-02-08T19:59:00.000+02:00", "replies_count": 0, "uuid": "258ab51bb4aa6c5c0a929e7549e5dbc162ad44a8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-alexion-pharma-q4-gaap-earnings-pe/brief-alexion-pharma-q4-gaap-earnings-per-share-0-13-idUSASB0C4PP", "ord_in_thread": 0, "title": "BRIEF-Alexion Pharma Q4 GAAP Earnings Per Share $0.13", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-alexion pharma", "sentiment": "negative"}, {"name": "alexion", "sentiment": "negative"}, {"name": "alexion pharmaceuticals inc", "sentiment": "negative"}, {"name": "gaap", "sentiment": "none"}, {"name": "alexion pharmaceuticals", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Alexion Pharmaceuticals Inc:\n* ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES FINANCIAL GUIDANCE FOR 2018\n* Q4 NON-GAAP EARNINGS PER SHARE $1.48 * Q4 GAAP EARNINGS PER SHARE $0.13 * Q4 REVENUE ROSE 9.5 PERCENT TO $909.7 MILLION * SEES FY 2018 REVENUE $3.85 BILLION TO $3.95 BILLION * SEES 2018 GAAP EARNINGS PER SHARE‍​ $4.35 TO $4.75 * SEES 2018 NON-GAAP EARNINGS PER SHARE $6.60 TO $6.80 * ALEXION PHARMACEUTICALS - GAAP INCOME TAX EXPENSE FOR QUARTER INCLUDES $45.8 MILLION CHARGE RELATED TO U.S. TAX REFORM\n* SEES 2018 GAAP OPERATING MARGIN 31% TO 34% * SEES 2018 NON-GAAP OPERATING MARGIN 48% TO 49% * ALEXION SAYS 2018 GUIDANCE ASSUMES GAAP EFFECTIVE TAX RATE OF 15 - 17 PERCENT (INCLUSIVE OF CO‘S PROVISIONAL ASSESSMENT OF U.S. TAX REFORM IMPACT) Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T19:59:00.000+02:00", "crawled": "2018-02-09T16:56:43.006+02:00", "highlightTitle": ""}